Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | ADCY5 | O95622 | 5/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | EP300 | Q09472 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19575471 | 0.92 | NSD3 (0.53) | LMNASMN1; SMN2ADCY5ADORA2AHPGD | |
| SCHEMBL19575394 | 0.92 | NSD3 (0.53) | LMNASMN1; SMN2ADCY5ADORA2AHPGD | |
| SCHEMBL20974516 | 0.92 | NSD3 (0.53) | LMNASMN1; SMN2ADCY5ADORA2AHPGD | |
| SCHEMBL19575403 | 0.92 | ADCY5 (0.51) | LMNASMN1; SMN2ADCY5ADORA2AHPGD | |
| SCHEMBL20972815 | 0.92 | ADCY5 (0.51) | LMNASMN1; SMN2ADCY5ADORA2AHPGD | |
| SCHEMBL20975139 | 0.91 | NSD3 (0.57) | LMNASMN1; SMN2ADCY5ADORA2ANSD3 | |
| SCHEMBL19575389 | 0.87 | ADCY5 (0.45) | LMNASMN1; SMN2ADCY5ADORA2ANSD3 | |
| SCHEMBL19575472 | 0.85 | ADCY5 (0.46) | LMNASMN1; SMN2ADCY5ADORA2AHPGD | |
| SCHEMBL26212056 | 0.85 | ADCY5 (0.46) | LMNASMN1; SMN2ADCY5ADORA2AHPGD | |
| SCHEMBL26217165 | 0.81 | NSD3 (0.53) | LMNASMN1; SMN2ADCY5ADORA2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236093-B2 | Adenine derivatives as protein kinase inhibitors | B.C.I. PHARMA (BE) | 2022-02-01 | — | — | US | disclosed |
| US-20190127379-A1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B.C.I. PHARMA (BE) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236093-B2 | Adenine derivatives as protein kinase inhibitors | ADK, TNNI3K, TNK2 | LMNA 873/4885SMN1; SMN2 2198/4885ADCY5 718/4885 |
| US-20190127379-A1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ADK, TNNI3K, TNK2 | LMNA 873/4885SMN1; SMN2 2198/4885ADCY5 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.